| Dear Fellow Investor, Studies find that multiple purchases by C-level executives signal strong annualized returns. Erasca, Inc. – SYM: ERAS
Recent Price: $4.34
Insider Action: 5 insiders buy $4 mil in shares
Description: Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. New “Living Missile” to Get $25 Billion in Funding TFF Pharmaceuticals, Inc. – SYM: TFFP
Recent Price: $1.05
Insider Action: 2 insiders buy $102K in shares
Description: TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas. The Small Biotech Scaring Big Pharma On January 10, 2018, a tiny biotech won a patent on a breakthrough treatment that could “Switch Off” the gene that causes Alzheimer’s disease. Eli Lilly, AbbiveVie, Amgen invested over $1 billion into this tiny company. That’s on top of the $40 million Bill Gates and Google Ventures already invested. See how you can profit from this rare opportunity here >>> Ultralife Corporation – SYM: ULBI
Recent Price: $4.05
Insider Action: 3 insiders buy $470K in shares
Description: Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables. The Communications Systems segment provides communications systems and accessories to support military communications systems, such as radio frequency amplifiers, power supplies and cables, connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, and integrated communication systems for fixed or vehicle applications comprising vehicle adapters, vehicle installed power enhanced rifleman appliqué systems, and SATCOM systems. This segment's military communications systems and accessories are designed to enhance and extend the operation of communications equipment, such as vehicle-mounted, manpack, and handheld transceivers. It sells its products under the Ultralife, Ultralife Thin Cell, Utralife HiRate, Ultralife and design, Ultra, Lithium Power, LithiumPower and Design, McDowell Research, AMTI, ABLE, ACCUTRONICS, ACCUPRO, ENTELLION, SWE Southwest Electronic Energy Group, SWE DRILL-DATA, and SWE SEASAFE brands through original equipment manufacturers, and industrial and defense supply distributors, as well as directly to the United States and international defense departments. In addition, the company sells its 9-volt battery to the broader consumer market through national and regional retail chains and online retailers. Ultralife Corporation serves government, defense, and commercial sectors. The company was incorporated in 1990 and is headquartered in Newark, New York. These 5 Tech Stocks Have 10x Potential If you had bought Netflix after the dot-com crash, you could have turned $1,000 into over half a million dollars in profit. And today – thanks to the tech crash – you have a similar opportunity. Luke Lango just named 5 tech stocks with 10x potential in a new report (one is trading for just $6).
Click here to claim your copy. Behind the Markets is brought to you by Behind the Markets, LLC. If you have any questions, please contact us at support@behindthemarkets.com, or call at 800-851-1965. Behind the Markets is a newsletter offered to the public on a subscription basis. While subscribers receive the benefit of Behind the Markets opinions, none of the information contained therein constitutes a recommendation from Behind the Markets that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You further understand that we will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in Behind the Markets may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Behind the Markets’ past results are not necessarily indicative of future performance.
Employees of Behind the Markets are subject to certain restrictions in transacting for their own benefit. SPECIFICALLY, EMPLOYEES ARE NOT PERMITTED TO BUY OR SELL ANY SECURITY RECOMMENDED FOR THREE (3) TRADING DAYS FOLLOWING THE ISSUE OF A REPORT OR UPDATE.
Behind the Markets’ Newsletter contains Behind the Markets’ own opinions, and none of the information contained therein constitutes a recommendation by Behind the Markets that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person.
You further understand that Behind the Markets will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter.
To the extent any of the information contained in Behind the Markets Newsletter may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
Behind the Markets’ past results are not necessarily indicative of future performance. DO NOT EMAIL Behind the Markets SEEKING PERSONALIZED INVESTMENT ADVICE, WHICH WE CANNOT PROVIDE.
The Editor's personal investing goals and risk tolerance may be substantially different from those discussed in the Newsletter and/or circumstances may have changed by the expiration of the three day restricted period, the investment actions taken by the Editor in the accounts the Editor directly or indirectly owns may vary from (and may even be contrary to) the advice and recommendations in the Newsletter.
Investing involves substantial risk. Neither the Editor, the publisher, nor any of their respective affiliates make any guarantee or other promise as to any results that may be obtained from using the Newsletter. While past performance may be analyzed in the Newsletter, past performance should not be considered indicative of future performance.
No subscriber should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing the prospectus and other public filings of the issuer.
To the maximum extent permitted by law, the Editor, the publisher and their respective affiliates disclaim any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations in the Newsletter prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses.
The Newsletter's commentary, analysis, opinions, advice and recommendations represent the personal and subjective views of the Editor and are subject to change at any time
without notice.
The information provided in the Newsletter is obtained from sources which the Editor believes to be reliable. However, the Editor has not independently verified or otherwise investigated all such information. Neither the Editor, the publisher, nor any of their respective affiliates guarantees the accuracy or completeness of any such information.
The Newsletter is not a solicitation or offer to buy or sell any securities. Further, the Newsletter is in no way intended to be a solicitation for any services offered by Behind the Markets
Neither the Editor, the publisher, nor any of their respective affiliates are responsible for any errors or omissions in the Newsletter. |
Post a Comment
Post a Comment